Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479135 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL123151 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL216035 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL8361882 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL20552191 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL235344 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL6682662 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL5699292 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL1053630 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL11552545 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227695-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227696-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227698-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| CN-117136061-A | SIK inhibitors and methods of use thereof | 索尔特戈公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116997548-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-2448600-B1 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-8962573-B2 | Compounds targeting the cation-independent mannose 6-phosphate receptor | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2448600-A1 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2012-05-09 | — | — | EP | disclosed |
| US-20120093795-A1 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2422817-A1 | Flavin-nucleic acid ligand conjugates | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011000958-A1 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-01-06 | — | — | WO | disclosed |
| US-7241884-B2 | Porphines-platinum metal complex compounds for organic electroluminescent device and organic electroluminescent device using them | LG ELECTRONICS INC. (KR) | 2007-07-10 | — | — | US | disclosed |
| US-20050137394-A1 | Porphines-platinum metal complex compounds for organic electroluminescent device and organic electroluminescent device using them | LG ELECTRONICS INC. (KR) | 2005-06-23 | — | — | US | disclosed |
| US-20030220400-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | Noe, Christian | 2003-11-27 | — | — | US | disclosed |
| US-6613795-B2 | Respiratory system disorders; muscle relaxants | Noe, Christian (DE) | 2003-09-02 | — | — | US | disclosed |
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CHRISTIAN NOE AND ERNST MUTSCHLER | 2002-11-21 | — | — | US | disclosed |
| US-6307060-B1 | ANTISPASMODIC AGENTS | Noe, Christian | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093795-A1 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | M6PR, IGF2R, MPI | KDM1A 4514/4885MAPT 2860/4885HSD11B1 3387/4885 |
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | KDM1A 2857/4885MAPT 4510/4885HSD11B1 159/4885 |
| US-20050137394-A1 | Porphines-platinum metal complex compounds for organic electroluminescent device and organic electroluminescent device using them | PPOX, FECH, PYCR1 | KDM1A 1803/4885MAPT 2311/4885HSD11B1 3826/4885 |
| US-20030220400-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | KDM1A 2857/4885MAPT 4510/4885HSD11B1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.